Biotech entity
gene-therapy is the sole category represented across all 2 tracked stories. AMT-130 is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. That works out to roughly 0.1 stories per week across a 132-day span. Source depth averages 2 original sources per story, versus 3.6 across the same-window beat baseline.
Last mentioned: Jul 12, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
gene-therapy is the sole category represented across all 2 tracked stories. AMT-130 is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. That works out to roughly 0.1 stories per week across a 132-day span. Source depth averages 2 original sources per story, versus 3.6 across the same-window beat baseline. The 7 average consequence score is above the beat benchmark of 6.2 in the same window. Matt Kapusta appears in 2 tracked Biotech stories published from March 3, 2026 through July 12, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 417 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Matt Kapusta. Shared-story counts are live from our verified record — not editorial picks.
FDA accepts AMT-130 Phase 1/2 data for BLA
The FDA reversed its earlier requirement for additional data, agreeing existing clinical data supports a near-term BLA submission for Huntington’s gene therapy.
FDA Type B Meeting
Planned follow-up meeting to define the Phase III pathway for AMT-130 in Huntington's disease.
Earnings Release
Company announces 2025 results and provides update on FDA Type A meeting.
AMT-260 Data
Clinical data expected from the Phase I/IIa study in refractory mesial temporal lobe epilepsy.
Planned BLA submission in Q3 2026
UniQure intends to submit a Biologics License Application for AMT-130 in the third quarter, pending alignment meeting on confirmatory study design.
Fiscal Year End
uniQure closes 2025 with $622.5M in cash and equivalents.
FDA’s acceptance of existing clinical data for uniQure’s AMT-130 gene therapy signals a major regulatory win, with the company on track for a BLA submission in Q3 2026 and a potential first-in-class approval for Huntington’s disease.
uniQure reported a robust $622.5 million cash position, extending its operational runway into late 2029. While clinical data for its Huntington’s disease candidate AMT-130 remains strong, the company is still seeking regulatory alignment with the FDA on a definitive Phase III pathway.
Matt Kapusta is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
